根据证交会的申报,2026年2月,Invivyd公司出售了220,000多股股份。 Executives at biopharma company Invivyd sold over 220,000 shares in February 2026, according to SEC filings.

2026年2月17日至18日, Invivyd(IVVD)的多个内部人士集体出售了220,000多股股票,个人销售量减少了两位数的百分比。 On February 17–18, 2026, multiple insiders at Invivyd (IVVD) sold over 220,000 shares collectively, with individual sales reducing holdings by double-digit percentages. 包括Julie Green、William Duke、Timothy Lee和Jill Andersen在内的执行官参与了交易,这些交易在日常的SEC表格4申报中披露。 Executives including Julie Green, William Duke, Timothy Lee, and Jill Andersen participated in the transactions, which were disclosed in routine SEC Form 4 filings. 库存于2月18日以1.65美元关闭,增加0.10美元,低于平均数量。 The stock closed at $1.65 on February 18, up $0.10, with below-average volume. 销售过程中没有新的临床公告或公司公告。 No new clinical or corporate announcements accompanied the sales. 生物制药公司Invivyd开发抗体治疗传染病,市值为3.84亿美元,分析师评级为"持有",目标价为8.00美元. Invivyd, a biopharma company developing antibody treatments for infectious diseases, has a market cap of $384.65 million, a consensus “Hold” analyst rating, and a target price of $8.00. 机构投资者拥有公司70.36%的股份。 Institutional investors own 70.36% of the company.